Mitomycin 2 mg

Mitomycin 2 mg is a chemotherapy medication used to treat various types of cancer, including:

1. Stomach cancer (gastric cancer)
2. Breast cancer
3. Pancreatic cancer
4. Lung cancer
5. Bladder cancer

Composition:

Each 2mg vial of Mitomycin contains Mitomycin-C, a folate analogue that inhibits the growth of cancer cells.

Mechanism of Action:

Mitomycin works by:

1. Inhibiting the synthesis of DNA, RNA, and protein, thereby preventing the growth and proliferation of cancer cells.
2. Inducing apoptosis (cell death) in cancer cells.

Indications:

Mitomycin is indicated for the treatment of:

1. Adenocarcinoma of the stomach (gastric cancer)
2. Adenocarcinoma of the breast
3. Adenocarcinoma of the pancreas
4. Adenocarcinoma of the lung
5. Transitional cell carcinoma of the bladder

Dosage:

The recommended dosage of Mitomycin is 2mg administered intravenously over 30 minutes every 6 weeks. The dose may be adjusted based on patient response and toxicity.

Side Effects:

Common side effects of Mitomycin include:

1. Nausea and vomiting
2. Diarrhea
3. Fatigue
4. Hair loss
5. Anemia
6. Thrombocytopenia
7. Neutropenia

Serious side effects can include:

1. Hemolytic uremic syndrome (HUS)
2. Cardiac events (e.g., cardiac arrhythmias, cardiac failure)
3. Respiratory events (e.g., respiratory failure, pneumonitis)
4. Neurological events (e.g., seizures, neuropathy)
5. Hepatotoxicity (e.g., liver failure, liver damage)

Recommendation:

Mitomycin should be administered under the guidance of a healthcare professional, and patients should be closely monitored for signs of side effects and treatment response.

Important Note:

• Patients with a history of cardiac disease or cardiac arrhythmias should be closely monitored while receiving Mitomycin.
• Patients with a history of kidney disease or liver dysfunction should receive dose reduction or close monitoring while receiving Mitomycin.
• Patients with a history of blood disorders should be closely monitored for signs of blood dyscrasias.
• Pregnant or breastfeeding women should not receive Mitomycin.
• Women of childbearing potential should use effective contraception while receiving Mitomycin.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of infection, such as fever, chills, or sore throat.
• Patients should be advised to report any changes in their appetite, nausea, or vomiting.
• Patients should be informed that they may experience hair loss, skin changes, or changes in their nails during treatment.

Storage and Handling:

• Store vials in the refrigerator between 2°C and 8°C (36°F and 46°F).
• Do not freeze or expose to direct sunlight.
• Use within 28 days of opening.
• Follow proper technique for reconstitution and administration to prevent contamination and ensure accurate dosing.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.